Hemodialysis Concentrates Related Products
Inventory Supply
FDA Clearance Information
The hemodialysis concentrates by Inventory Supply were cleared through the FDA 510k pathway on June 3, 1987. They are classified as Class 2 medical devices.
What It Is
FDA-Cleared Indications
- For use as dialysate concentrates with hemodialysis systems.
- For treatment of patients whose kidneys cannot adequately remove waste products and regulate fluid and electrolyte balance.
Clinical Applications
- Preparation of dialysate for maintenance hemodialysis.
- Use during hemodialysis for patients with chronic kidney disease or kidney failure.
- Support of electrolyte and acid-base management during a dialysis treatment.
- Use with compatible dialysis equipment according to the concentrate and machine labeling.
Evidence Summary
Reported Outcomes
Safety Profile
Evidence Limitations
Practical Considerations
- Concentrates must be mixed or proportioned with the specified water and dialysis machine system; incorrect dilution can cause serious electrolyte or acid-base abnormalities.
- The concentrate formulation must be compatible with the dialysis prescription, including sodium, potassium, calcium, magnesium, bicarbonate or acetate, and glucose when present.
- Products should be stored, handled, and inspected according to labeling to prevent contamination, deterioration, or use after expiration.
- This is a dialysis fluid product rather than an implantable device, so MRI safety labeling is generally not the primary concern; the dialysis machine and other connected equipment require separate evaluation.
- Use requires a functioning hemodialysis system and trained clinical staff; the appropriate formulation is selected based on the patient's prescription and laboratory results.
Frequently Asked Questions
What are the clinical indications for hemodialysis concentrates?
Hemodialysis concentrates are indicated for use in patients requiring dialysis to manage chronic kidney disease or end-stage renal disease.
What outcomes have been reported in clinical studies?
Studies report effective management of electrolyte balance and waste removal, with some evidence suggesting reduced vascular calcification and improved cardiovascular health.
What complications have been reported?
Safety data indicate potential vascular calcification associated with increased trimethylamine N-oxide levels in hemodialysis patients.